At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study.

PURPOSE: Frequent in-clinic cancer treatment can be burdensome, particularly for older adults and patients with limited mobility. This study aimed to assess the safety, feasibility, and patient experience of at-home subcutaneous (SC) atezolizumab injection administration in patients with non-small cell lung cancer (NSCLC).

PATIENTS AND

METHODS

This feasibility study included five patients with NSCLC treated with atezolizumab SC injections (1,875 mg every 21 days). The first three treatment cycles were administered in clinic, followed by nurse-administered home treatment. Patients underwent routine laboratory testing, telehealth visits, and standard disease monitoring. Safety, injection timeliness, treatment compliance, and patient satisfaction were evaluated over a total of 70 treatment cycles.

RESULTS

Of 70 total SC injections, 65 (93%) were delivered on time. No delays were attributable to atezolizumab SC administration. Two of five patients (40%) experienced an adverse event. Home administration required a shorter measured administration duration than in-clinic treatment (42.3 vs. 86.7 minutes). Digital monitoring engagement was limited. Mean Likert scores showed high overall satisfaction with drug administration (3.3/4) and preference for subcutaneous over intravenous administration (3.2/4).

CONCLUSION

At-home atezolizumab SC administration was feasible in this small feasibility study and was associated with high patient satisfaction and shorter measured administration time.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier is NCT05340309.